Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are PermeaDerm, a transparent, biosynthetic bilayer wound matrix used for temporary wound coverage (temporization) after surgical excision of burns or trauma, and Cohealyx, a bovine-derived collagen dermal matrix used by burn and trauma surgeons to treat severe wounds and full-thickness burns by accelerating blood vessel formation in order to prepare damaged wound beds for skin autografts.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | 2026-08-31 10:44:24 | 10.13 | -0.21 | -2.03 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RCEL | 0001762303 | AVITA Medical, Inc. | US05380C1027 | 5299003E8ETEQDDQ3826 | 202578762 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 28159 AVENUE STANFORD | VALENCIA | CA | 91355 | UNITED STATES | US | 661-568-1317 | 28159 AVENUE STANFORD, VALENCIA, CA, 91355 | 28159 AVENUE STANFORD, VALENCIA, CA, 91355 | Avita Therapeutics, Inc. | Regenerative medicine | 1993 | — | — | http://www.avitamedical.com | 138,669,045 | 30,926,847 | 30,926,847 | Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are PermeaDerm, a transparent, biosynthetic bilayer wound matrix used for temporary wound coverage (temporization) after surgical excision of burns or trauma, and Cohealyx, a bovine-derived collagen dermal matrix used by burn and trauma surgeons to treat severe wounds and full-thickness burns by accelerating blood vessel formation in order to prepare damaged wound beds for skin autografts. | 2026-08-27 21:21:37 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 138,669,045 | -64,765,786 | -31.8361 | 30,631,794 | 4,274,252 | 16.2164 |
| 2024 | 203,434,831 | -228,426,191 | -52.8934 | 26,357,542 | 650,880 | 2.532 |
| 2023 | 431,861,022 | 314,399,984 | 267.6632 | 25,706,662 | 410,576 | 1.6231 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Nicole Kelsey | SVP | 2025 | 458,455 | 91,800 | — | — | 22,806 | 957,427 |
| James Corbett | Chief Executive Officer | 2025 | 569,302 | 0 | — | — | 196,040 | 1,407,715 |
| Cary Vance | Chief Executive Officer | 2025 | 137,475 | 140,000 | — | — | 578 | 278,053 |
| David O'Toole | Chief Financial Officer | 2025 | 490,916 | 98,600 | — | — | 55,749 | 1,532,265 |
| David O'Toole | Chief Financial Officer | 2024 | 459,253 | 195,500 | — | — | 54,109 | 1,777,528 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 226 |
| 2024 | 260 |
| 2023 | 207 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 71,610,000 | 64,251,000 | 50,143,000 |
| Cost Of Revenue | 12,794,000 | 9,094,000 | 7,780,000 |
| Gross Profit | 58,816,000 | 55,157,000 | 42,363,000 |
| Research And Development Expenses | 20,839,000 | 20,360,000 | 20,821,000 |
| General And Administrative Expenses | 27,373,000 | 33,195,000 | 28,334,000 |
| Operating Expenses | 101,350,000 | 111,750,000 | 86,446,000 |
| Operating Income | -42,534,000 | -56,593,000 | -42,655,000 |
| Net Income | -48,587,000 | -61,845,000 | -35,381,000 |
| Earnings Per Share Basic | -1.74 | -2.39 | 1.4 |
| Earnings Per Share Diluted | -1.74 | -2.39 | 1.4 |
| Weighted Average Shares Outstanding Basic | 27,860,784 | 25,883,056 | 25,331,264 |
| Weighted Average Shares Outstanding Diluted | 27,860,784 | 25,883,056 | 25,331,264 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 10,243,000 | 14,050,000 | 22,118,000 |
| Marketable Securities Current | 7,942,000 | 21,835,000 | 66,939,000 |
| Accounts Receivable | 9,086,000 | 11,786,000 | 7,664,000 |
| Inventories | 6,926,000 | 7,269,000 | 5,596,000 |
| Non Trade Receivables | — | 56,000 | 30,000 |
| Other Assets Current | 1,293,000 | 2,004,000 | 18,000 |
| Total Assets Current | 35,490,000 | 57,000,000 | 104,006,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 8,630,000 | 10,018,000 | 1,877,000 |
| Other Assets Non Current | 612,000 | 546,000 | 355,000 |
| Total Assets Non Current | 20,902,000 | 22,711,000 | 7,634,000 |
| Total Assets | 56,392,000 | 79,711,000 | 111,640,000 |
| Accounts Payable | 8,959,000 | 6,294,000 | 3,793,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 42,984,000 | — | — |
| Other Liabilities Current | 2,645,000 | 1,319,000 | 1,266,000 |
| Total Liabilities Current | 62,677,000 | 20,158,000 | 13,199,000 |
| Long Term Debt | 0 | 42,245,000 | 39,812,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 10,365,000 | 54,810,000 | 48,692,000 |
| Total Liabilities | 73,042,000 | 74,968,000 | 61,891,000 |
| Common Stock | 3,000 | 3,000 | 3,000 |
| Retained Earnings | -408,401,000 | -359,814,000 | -297,969,000 |
| Accumulated Other Comprehensive Income | -1,367,000 | -1,939,000 | -1,887,000 |
| Total Shareholders Equity | -16,650,000 | 4,499,000 | 49,056,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 2,347,000 | 1,126,000 | 632,000 |
| Share Based Compensation Expense | 9,519,000 | 13,496,000 | 8,384,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | 468,000 | 2,160,000 | 3,693,000 |
| Change In Non Trade Receivables | — | 26,000 | -868,000 |
| Change In Other Assets | 65,000 | 191,000 | 233,000 |
| Change In Accounts Payable | 2,745,000 | 340,000 | 809,000 |
| Change In Other Liabilities | -2,638,000 | 2,479,000 | 1,347,000 |
| Cash From Operating Activities | -31,195,000 | -48,939,000 | -38,011,000 |
| Purchases Of Marketable Securities | 13,309,000 | 24,504,000 | 78,757,000 |
| Sales Of Marketable Securities | 27,500,000 | 71,200,000 | 2,372,000 |
| Acquisition Of Property Plant And Equipment | 1,005,000 | 9,171,000 | 1,381,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 12,452,000 | 37,363,000 | 1,607,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 14,792,000 | 2,135,000 | 957,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | 38,762,000 |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 14,936,000 | 3,508,000 | 40,374,000 |
| Change In Cash | -3,807,000 | -8,068,000 | 3,954,000 |
| Cash At End Of Period | 10,243,000 | 14,050,000 | 22,118,000 |
| Income Taxes Paid | 15,000 | 41,000 | 44,000 |
| Interest Paid | 4,980,000 | 5,359,000 | 1,143,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.74 | -2.39 | 1.4 |
| Price To Earnings Ratio | -1.9828 | -5.3556 | 9.8 |
| Earnings Growth Rate | -27.1967 | -270.7143 | 30.8411 |
| Price Earnings To Growth Ratio | 0.0729 | 0.0198 | 0.3178 |
| Book Value Per Share | -0.5976 | 0.1832 | 1.9639 |
| Price To Book Ratio | -5.773 | 69.851 | 6.986 |
| Ebitda | -41,221,000 | -55,317,000 | -33,562,000 |
| Enterprise Value | 128,860,704.8 | 359,498,116.8 | 365,238,942.08 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -2.5816 | 9.3899 | 0.8116 |
| Capital Expenditures | 959,000 | 9,267,000 | 1,309,000 |
| Free Cash Flow | -32,154,000 | -58,206,000 | -39,320,000 |
| Return On Equity | 2.9181 | -13.7464 | -0.7212 |
| One Year Beta | 1.1344 | 1.6801 | 1.6114 |
| Three Year Beta | 1.372 | 1.5009 | 1.4784 |
| Five Year Beta | 1.4086 | 1.5289 | 1.5447 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| O'Toole David D | CFO | 2026-06-12 | 2,000 | A | 152,927 |
| O'Toole David D | CFO | 2026-06-12 | 2,000 | A | 152,927 |
| Woody Joseph Fralin | Director | 2026-06-09 | 5,000 | A | 97,761 |
| Woody Joseph Fralin | Director | 2026-06-09 | 5,000 | A | 102,761 |
| Woody Joseph Fralin | Director | 2026-06-09 | 5,200 | A | 107,961 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| MERCER GLOBAL ADVISORS INC /ADV | 2026-06-30 | 48,073 | 11,640 | 4.13 |
| GOLDMAN SACHS GROUP INC | 2026-06-30 | 316,924 | 76,737 | 4.13 |
| Jain Global LLC | 2026-06-30 | 127,101 | 30,775 | 4.13 |
| CITADEL ADVISORS LLC | 2026-06-30 | 65,254 | 15,800 | 4.13 |
| CITADEL ADVISORS LLC | 2026-06-30 | 87,746 | 21,246 | 4.13 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VANGUARD VALLEY FORGE FUNDS | 2026-06-30 | INSTITUTIONAL SHARES | VBAIX | 18,756 | 77,462.28 | 0.0001 |
| VANGUARD VALLEY FORGE FUNDS | 2026-06-30 | ADMIRAL SHARES | VBIAX | 18,756 | 77,462.28 | 0.0001 |
| VANGUARD VALLEY FORGE FUNDS | 2026-06-30 | INVESTOR SHARES | VBINX | 18,756 | 77,462.28 | 0.0001 |
| VANGUARD INDEX FUNDS | 2026-06-30 | Institutional Select Shares | VSTSX | 958,401 | 3,958,196.13 | 0.0002 |
| VANGUARD INDEX FUNDS | 2026-06-30 | Institutional Plus Shares | VSMPX | 958,401 | 3,958,196.13 | 0.0002 |